Citations (53)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Ahmed Sayed, Malak Munir, Noor Eweis, Doaa Wael, Omar Shazly, Ahmed K. Awad, Marihan A. Elbadawy & Sanaa Eissa. (2020) An overview on precision therapy in bladder cancer. Expert Review of Precision Medicine and Drug Development 5:5, pages 347-361.
Read now
Read now
Te-Fu Tsai, Ji-Fan Lin, Kuang-Yu Chou, Yi-Chia Lin, Hung-En Chen & Thomas I-Sheng Hwang. (2018) miR-99a-5p acts as tumor suppressor via targeting to mTOR and enhances RAD001-induced apoptosis in human urinary bladder urothelial carcinoma cells. OncoTargets and Therapy 11, pages 239-252.
Read now
Read now
Einar F Sverrisson, Patrick N Espiritu & Philippe E Spiess. (2013) New therapeutic targets in the management of urothelial carcinoma of the bladder. Research and Reports in Urology 5, pages 53-65.
Read now
Read now
Rosário Pinto-Leite, Regina Arantes-Rodrigues, Carlos Palmeira, Isabel Gaivão, Maria
Luís Cardoso, Aura Colaço, Lúcio Santos & Paula Oliveira. (2012) Everolimus Enhances Gemcitabine-Induced Cytotoxicity in Bladder-Cancer Cell Lines. Journal of Toxicology and Environmental Health, Part A 75:13-15, pages 788-799.
Read now
Read now
Articles from other publishers (49)
Dimitrios Makrakis, Jonathan L. Wright, Martine P. Roudier, Jose Garcia, Funda Vakar-Lopez, Michael P. Porter, Yan Wang, Atreya Dash, Daniel Lin, George Schade, Brian Winters, Xiotun Zhang, Peter Nelson, Elahe Mostaghel, Heather H. Cheng, Michael Schweizer, Sarah K. Holt, John L. Gore, Evan Y. Yu, Hung Ming Lam & Bruce Montgomery. (2023) A Phase 1/2 Study of Rapamycin and Cisplatin/Gemcitabine for Treatment of Patients With Muscle-Invasive Bladder Cancer. Clinical Genitourinary Cancer 21:2, pages 265-272.
Crossref
Crossref
Zhiyong Shen, Dong Xue, Kun Wang, Facai Zhang, Jiaqi Shi, Benzhong Jia, Dan Yang, Qianjin Zhang, Shuai Zhang, Hongyu Jiang, Daiqin Luo, Xueying Li, Quliang Zhong, Junhao Zhang, Zheng Peng, Yu Han, Chongyang Sima, Xiaozhou He & Lin Hao. (2022) Metformin exerts an antitumor effect by inhibiting bladder cancer cell migration and growth, and promoting apoptosis through the PI3K/AKT/mTOR pathway. BMC Urology 22:1.
Crossref
Crossref
Jonathan Thomas & Guru Sonpavde. (2022) Molecularly Targeted Therapy towards Genetic Alterations in Advanced Bladder Cancer. Cancers 14:7, pages 1795.
Crossref
Crossref
Jianya Huan, Petros Grivas, Jasmine Birch & Donna E. Hansel. (2022) Emerging Roles for Mammalian Target of Rapamycin (mTOR) Complexes in Bladder Cancer Progression and Therapy. Cancers 14:6, pages 1555.
Crossref
Crossref
Tamires Cunha Almeida & Glenda Nicioli da Silva. (2021) Resveratrol effects in bladder cancer: A mini review. Genetics and Molecular Biology 44:1.
Crossref
Crossref
Constantine Alifrangis, Ursula McGovern, Alex Freeman, Thomas Powles & Mark Linch. (2019) Molecular and histopathology directed therapy for advanced bladder cancer. Nature Reviews Urology 16:8, pages 465-483.
Crossref
Crossref
Marie-Lisa Eich, Aline C. Tregnago, Sheila F. Faraj, Doreen N. Palsgrove, Kazutoshi Fujita, Stephania M. Bezerra, Enrico Munari, Rajni Sharma, Alcides Chaux & George J. Netto. (2018) Insulin-like growth factor-1 receptor expression in upper tract urothelial carcinoma. Virchows Archiv 474:1, pages 21-27.
Crossref
Crossref
Marina Pulido, Guilhem Roubaud, Anne-Laure Cazeau, Hakim Mahammedi, Lionel Vedrine, Florence Joly, Loic Mourey, Christian Pfister, Alejandro Goberna, Barbara Lortal, Carine Bellera, Philippe Pourquier & Nadine Houédé. (2018) Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer. BMC Cancer 18:1.
Crossref
Crossref
Brian R. Winters, Funda Vakar-Lopez, Lisha Brown, Bruce Montgomery, Roland Seiler, Peter C. Black, Joost L. Boormans, Marc Dall′Era, Elai Davincioni, James Douglas, Ewan A. Gibb, Bas W.G. van Rhijn, Michiel S. van der Heijden, Andrew C. Hsieh, Jonathan L. Wright & Hung-Ming Lam. (2018) Mechanistic target of rapamycin (MTOR) protein expression in the tumor and its microenvironment correlates with more aggressive pathology at cystectomy. Urologic Oncology: Seminars and Original Investigations 36:7, pages 342.e7-342.e14.
Crossref
Crossref
Sandy T. Liu, Gavin Hui, Colleen Mathis, Karim Chamie, Allan J. Pantuck & Alexandra Drakaki. (2018) The Current Status and Future Role of the Phosphoinositide 3 Kinase/AKT Signaling Pathway in Urothelial Cancer: An Old Pathway in the New Immunotherapy Era. Clinical Genitourinary Cancer 16:2, pages e269-e276.
Crossref
Crossref
Liang Yan, Qi Li, Juan Yang & Baoping Qiao. (2017) TPX2‐p53‐GLIPR1 regulatory circuitry in cell proliferation, invasion, and tumor growth of bladder cancer. Journal of Cellular Biochemistry 119:2, pages 1791-1803.
Crossref
Crossref
Bassel G. Bachir, Luis Souhami, Jose João Mansure, Fabio Cury, Marie Vanhuyse, Fadi Brimo, Armen G. Aprikian, Simon Tanguay, Jeremy Sturgeon & Wassim Kassouf. (2017) Phase I Clinical Trial of Everolimus Combined with Trimodality Therapy in Patients with Muscle-Invasive Bladder Cancer. Bladder Cancer 3:2, pages 105-112.
Crossref
Crossref
Anya Alayev, Rachel S. Salamon, Naomi S. Schwartz, Adi Y. Berman, Sara L. Wiener & Marina K. Holz. (2017) Combination of Rapamycin and Resveratrol for Treatment of Bladder Cancer. Journal of Cellular Physiology 232:2, pages 436-446.
Crossref
Crossref
Nikolaos Koletsas, Triantafyllia Koletsa, Spyros Choidas, Konstantinos Anagnostopoulos, Stavros Touloupidis, Thomas Zaramboukas, Georgia Raptou, Nikolaos Papadopoulos & Maria Lambropoulou. (2017) Immunohistochemical Investigation of HER/AKT/mTOR Pathway and Cellular Adhesion Molecules in Urothelial Carcinomas. Pathology Research International 2017, pages 1-7.
Crossref
Crossref
Rui Yu, Bi-xia Yu, Jun-feng Chen, Xiu-yi Lv, Ze-jun Yan, Yue Cheng & Qi Ma. (2016) Anti-tumor effects of Atractylenolide I on bladder cancer cells. Journal of Experimental & Clinical Cancer Research 35:1.
Crossref
Crossref
Sanhita Shrivastava, Jose Joao Mansure, Wael Almajed, Fabio Cury, Gerardo Ferbeyre, Marija Popovic, Jan Seuntjens & Wassim Kassouf. (2016) The Role of HMGB1 in Radioresistance of Bladder Cancer. Molecular Cancer Therapeutics 15:3, pages 471-479.
Crossref
Crossref
Mathieu Rouanne, Yohann Loriot, Thierry Lebret & Jean-Charles Soria. (2016) Novel therapeutic targets in advanced urothelial carcinoma. Critical Reviews in Oncology/Hematology 98, pages 106-115.
Crossref
Crossref
Hsiao-Yen Hsieh, Cheng-Huang Shen, Ru-Inn Lin, Yu-Min Feng, Shih-Yuan Huang, Yuan-Hung Wang, Shu-Fen Wu, Cheng-Da Hsu & Michael W.Y. Chan. (2016) Cyproheptadine exhibits antitumor activity in urothelial carcinoma cells by targeting GSK3β to suppress mTOR and β-catenin signaling pathways. Cancer Letters 370:1, pages 56-65.
Crossref
Crossref
Simona Wagner & Janet E. Dancey. 2016. mTOR Inhibition for Cancer Therapy: Past, Present and Future. mTOR Inhibition for Cancer Therapy: Past, Present and Future
229
249
.
Qing Zhang, Junlong Zhuang, Yongming Deng, Xiaozhi Zhao, Bo Tang, Dongwei Yao, Wei Zhao, Cunjie Chang, Qun Lu, Wei Chen, Shiwei Zhang, Changwei Ji, Lin Cao & Hongqian Guo. (2015) GOLPH3 is a potential therapeutic target and a prognostic indicatior of poor survival in bladder cancer treated by cystectomy. Oncotarget 6:31, pages 32177-32192.
Crossref
Crossref
MASASHI MATSUSHIMA, EIJI KIKUCHI, KAZUHIRO MATSUMOTO, SEIYA HATTORI, TOSHIKAZU TAKEDA, TAKEO KOSAKA, AKIRA MIYAJIMA & MOTOTSUGU OYA. (2015) Intravesical dual PI3K/mTOR complex 1/2 inhibitor NVP-BEZ235 therapy in an orthotopic bladder cancer model. International Journal of Oncology 47:1, pages 377-383.
Crossref
Crossref
Emmet J. Jordan & Gopa Iyer. (2015) Targeted Therapy in Advanced Bladder Cancer. Urologic Clinics of North America 42:2, pages 253-262.
Crossref
Crossref
Mahmoud Chehab, Tiffany Caza, Kamil Skotnicki, Steve Landas, Gennady Bratslavsky, Mehdi Mollapour & Dimitra Bourboulia. (2015) Targeting Hsp90 in urothelial carcinoma. Oncotarget 6:11, pages 8454-8473.
Crossref
Crossref
Byung Hoon Chi, Soon-Ja Kim, Ho Kyung Seo, Hye-Hyun Seo, Sang-Jin Lee, Jong Kyou Kwon, Tae-Jin Lee & In Ho Chang. (2015) P70S6K and Elf4E Dual Inhibition Is Essential to Control Bladder Tumor Growth and Progression in Orthotopic Mouse Non-muscle Invasive Bladder Tumor Model. Journal of Korean Medical Science 30:3, pages 308.
Crossref
Crossref
Nadine Houédé & Philippe Pourquier. (2015) Targeting the genetic alterations of the PI3K–AKT–mTOR pathway: Its potential use in the treatment of bladder cancers. Pharmacology & Therapeutics 145, pages 1-18.
Crossref
Crossref
Sounak Gupta & Donna E. Hansel. 2015. Urological Oncology. Urological Oncology
563
590
.
DU G. MOON, SANG E. LEE, MI M. OH, SANG C. LEE, SEONG J. JEONG, SUNG K. HONG, CHEOL Y. YOON, SEOK S. BYUN, HONG S. PARK & JUN CHEON. (2014) NVP-BEZ235, a dual PI3K/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells. International Journal of Oncology 45:3, pages 1027-1035.
Crossref
Crossref
Marie N. Becker, Kevin J. Wu, Laura A. Marlow, Pamela A. Kreinest, Christina A. vonRoemeling, John A. Copland & Christopher R. Williams. (2014) The combination of an mTORc1/TORc2 inhibitor with lapatinib is synergistic in bladder cancer in vitro. Urologic Oncology: Seminars and Original Investigations 32:3, pages 317-326.
Crossref
Crossref
Pasquale Cirone, Catharine J. Andresen, Jeetendra R. Eswaraka, Patrick B. Lappin & Cedo M. Bagi. (2014) Patient-derived xenografts reveal limits to PI3K/mTOR- and MEK-mediated inhibition of bladder cancer. Cancer Chemotherapy and Pharmacology 73:3, pages 525-538.
Crossref
Crossref
Rosário Pinto-Leite, Regina Arantes-Rodrigues, Rita Ferreira, Carlos Palmeira, Aura Colaço, Vítor Moreira da Silva, Paula Oliveira & Lúcio Lara Santos. (2014) Temsirolimus improves cytotoxic efficacy of cisplatin and gemcitabine against urinary bladder cancer cell lines. Urologic Oncology: Seminars and Original Investigations 32:1, pages 41.e11-41.e22.
Crossref
Crossref
Tao Zhang, Peng Guo, Yinan Zhang, Hui Xiong, Xiao Yu, Shan Xu, Xinyang Wang, Dalin He & Xunbo Jin. (2013) The Antidiabetic Drug Metformin Inhibits the Proliferation of Bladder Cancer Cells in Vitro and in Vivo. International Journal of Molecular Sciences 14:12, pages 24603-24618.
Crossref
Crossref
Enrico Munari, Kazutoshi Fujita, Sheila Faraj, Alcides Chaux, Nilda Gonzalez-Roibon, Jessica Hicks, Alan Meeker, Norio Nonomura & George J. Netto. (2013) Dysregulation of mammalian target of rapamycin pathway in upper tract urothelial carcinoma. Human Pathology 44:12, pages 2668-2676.
Crossref
Crossref
Carmen Vasconcelos-Nóbrega, Rosario Pinto-Leite, Regina Arantes-Rodrigues, Rita Ferreira, Paulo Brochado, Maria L. Cardoso, Carlos Palmeira, Alexandre Salvador, Catarina I. Guedes-Teixeira, Aura Colaço, Luis F. Palomino, Carlos Lopes, Lúcio Santos & Paula A. Oliveira. (2013) In vivo and in vitro effects of RAD001 on bladder cancer. Urologic Oncology: Seminars and Original Investigations 31:7, pages 1212-1221.
Crossref
Crossref
Mona Fahmy, Jose Joao Mansure, Fadi Brimo, Faysal A. Yafi, Robert Segal, Abdulaziz Althunayan, Jessica Hicks, Alan Meeker, George Netto & Wassim Kassouf. (2013) Relevance of the mammalian target of rapamycin pathway in the prognosis of patients with high-risk non–muscle invasive bladder cancer. Human Pathology 44:9, pages 1766-1772.
Crossref
Crossref
Matthew I. Milowsky, Gopa Iyer, Ashley M. Regazzi, Hikmat Al-Ahmadie, Scott R. Gerst, Irina Ostrovnaya, Lan L. Gellert, Rana Kaplan, Ilana R. Garcia-Grossman, Deepa Pendse, Arjun V. Balar, Anne Marie Flaherty, Alisa Trout, David B. Solit & Dean F. Bajorin. (2013) Phase II study of everolimus in metastatic urothelial cancer. BJU International 112:4, pages 462-470.
Crossref
Crossref
Roland Nassim, Jose Joao Mansure, Simone Chevalier, Fabio Cury & Wassim Kassouf. (2013) Combining mTOR Inhibition with Radiation Improves Antitumor Activity in Bladder Cancer Cells In Vitro and In Vivo: A Novel Strategy for Treatment. PLoS ONE 8:6, pages e65257.
Crossref
Crossref
Tetsuo Nishi, Kenta Iwasaki, Norifumi Ohashi, Chie Tanaka, Daisuke Kobayashi, Goro Nakayama, Masahiko Koike, Michitaka Fujiwara, Takaaki Kobayashi & Yasuhiro Kodera. (2013) Phosphorylation of 4E-BP1 predicts sensitivity to everolimus in gastric cancer cells. Cancer Letters 331:2, pages 220-229.
Crossref
Crossref
Nilda D. Gonzalez-Roibon, Alcides Chaux, Turki Al-Hussain, Adeboye O. Osunkoya, Stephania Martins Bezerra, Jessica Hicks, Jonathan I. Epstein & George J. Netto. (2013) Dysregulation of mammalian target of rapamycin pathway in plasmacytoid variant of urothelial carcinoma of the urinary bladder. Human Pathology 44:4, pages 612-622.
Crossref
Crossref
Rosário Pinto-Leite, Regina Arantes-Rodrigues, Carlos Palmeira, Bruno Colaço, Carlos Lopes, Aura Colaço, Céu Costa, Vítor Moreira da Silva, Paula Oliveira & Lúcio Santos. (2013) Everolimus combined with cisplatin has a potential role in treatment of urothelial bladder cancer. Biomedicine & Pharmacotherapy 67:2, pages 116-121.
Crossref
Crossref
Chuanliang Xu, Qinsong Zeng, Weidong Xu, Li Jiao, Yanqiong Chen, Zhensheng Zhang, Chengyao Wu, Taile Jin, Anyin Pan, Rongchao Wei, Bo Yang & Yinghao Sun. (2013) miRNA-100 Inhibits Human Bladder Urothelial Carcinogenesis by Directly Targeting mTOR. Molecular Cancer Therapeutics 12:2, pages 207-219.
Crossref
Crossref
Alcides Chaux, Eva Compérat, Justine Varinot, Jessica Hicks, Kristen Lecksell, Jason Solus & George J. Netto. (2013) High Levels of Phosphatase and Tensin Homolog Expression Are Associated With Tumor Progression, Tumor Recurrence, and Systemic Metastases in pT1 Urothelial Carcinoma of the Bladder: A Tissue Microarray Study of 156 Patients Treated by Transurethral Resection. Urology 81:1, pages 116-122.
Crossref
Crossref
Penelope Korkolopoulou, Georgia Levidou, Eleni‐Andriana Trigka, Niki Prekete, Maria Karlou, Irene Thymara, Stratigoula Sakellariou, Paraskevi Fragkou, Dimitrios Isaiadis, Petros Pavlopoulos, Efstratios Patsouris & Angelica A. Saetta. (2012) A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3‐kinase/v‐akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma. BJU International 110:11c.
Crossref
Crossref
H. Gerullis, C. Eimer, T. H. Ecke, E. Georgas, C. Freitas, S. Kastenholz, C. Arndt, C. Heusch & T. Otto. (2012) A phase II trial of temsirolimus in second-line metastatic urothelial cancer. Medical Oncology 29:4, pages 2870-2876.
Crossref
Crossref
Holger Gerullis, Thomas Otto & Thorsten H. Ecke. (2012) Targeted agents in second-line bladder cancer therapy. Anti-Cancer Drugs 23:10, pages 1003-1015.
Crossref
Crossref
E. Seront, S. Rottey, B. Sautois, J. Kerger, L.A. D'Hondt, V. Verschaeve, J.-L. Canon, C. Dopchie, J.M. Vandenbulcke, N. Whenham, J.C. Goeminne, M. Clausse, D. Verhoeven, P. Glorieux, S. Branders, P. Dupont, J. Schoonjans, O. Feron & J.-P. Machiels. (2012) Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers. Annals of Oncology 23:10, pages 2663-2670.
Crossref
Crossref
Igor Makhlin, Jiaru Zhang, Christopher J. Long, Karthik Devarajan, Yan Zhou, Andres J. Klein-Szanto, Min Huang, Jonathan Chernoff & Stephen A. Boorjian. (2011) The mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers. BJU International 108:2b, pages E84-E90.
Crossref
Crossref
Edmund Chiong, I-Ling Lee, Ali Dadbin, Anita L. Sabichi, Loleta Harris, Diana Urbauer, David J. McConkey, Rian J. Dickstein, Tiewei Cheng & H. Barton Grossman. (2011) Effects of mTOR Inhibitor Everolimus (RAD001) on Bladder Cancer Cells. Clinical Cancer Research 17:9, pages 2863-2873.
Crossref
Crossref
Satish K. Tickoo, Matthew I. Milowsky, Nitin Dhar, Maria E. Dudas, David J. Gallagher, Hikmat Al-Ahmadie, Anuradha Gopalan, Samson W. Fine, Nicole Ishill, Dean F. Bajorin & Victor E. Reuter. (2011) Hypoxia-inducible factor and mammalian target of rapamycin pathway markers in urothelial carcinoma of the bladder: possible therapeutic implications. BJU International 107:5, pages 844-849.
Crossref
Crossref
Derek Raghavan. (2010) Bladder Cancer: Optimal Application of Preclinical Models to Suitable Translational Questions. Science Translational Medicine 2:22.
Crossref
Crossref